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Original Investigation | Oncology

Development and Assessment of a Clinical Calculator for Estimating the Likelihood
of Recurrence and Survival Among Patients With Locally Advanced Rectal Cancer
Treated With Chemotherapy, Radiotherapy, and Surgery
Martin R. Weiser, MD; Joanne F. Chou, MPH; Ajaratu Keshinro, MD; William C. Chapman Jr, MD; Philip S. Bauer, MD; Matthew G. Mutch, MD; Parag J. Parikh, MD;
Andrea Cercek, MD; Leonard B. Saltz, MD; Marc J. Gollub, MD; Paul B. Romesser, MD; Christopher H. Crane, MD; Jinru Shia, MD; Arnold J. Markowitz, MD;
Julio Garcia-Aguilar, MD, PhD; Mithat Gönen, PhD; for the Colorectal Cancer Disease Management Team of Memorial Sloan Kettering Cancer Center

Abstract

Key Points

IMPORTANCE Predicting outcomes in patients receiving neoadjuvant therapy for rectal cancer is
challenging because of tumor downstaging. Validated clinical calculators that can estimate
recurrence-free survival (RFS) and overall survival (OS) among patients with rectal cancer who have
received multimodal therapy are needed.

Question Do clinical calculators provide
more useful estimates of the likelihood
of rectal cancer recurrence and patient
survival than American Joint Committee
on Cancer staging and neoadjuvant

OBJECTIVE To develop and validate clinical calculators providing estimates of rectal cancer

rectal score?

recurrence and survival that are better for individualized decision-making than the American Joint

Findings In this prognostic study of

Committee on Cancer (AJCC) staging system or the neoadjuvant rectal (NAR) score.

1400 patients with locally advanced
rectal cancer, the use of clinical

DESIGN, SETTING, AND PARTICIPANTS This prognostic study developed risk models, graphically

calculators incorporating pathological

represented as nomograms, for patients with incomplete pathological response using Cox

response, postoperative pathological

proportional hazards and multivariable regression analyses with restricted cubic splines. Because

tumor category, number of positive

patients with complete pathological response to neoadjuvant therapy had uniformly favorable

lymph nodes, tumor location, and the

outcomes, their predictions were obtained separately. The study included 1400 patients with stage

presence of venous and perineural

II or III rectal cancer who received treatment with chemotherapy, radiotherapy, and surgery at 2

invasion (plus patient age for predicting

comprehensive cancer centers (Memorial Sloan Kettering [MSK] Cancer Center and Siteman Cancer

overall survival) more accurately

Center [SCC]) between January 1, 1998, and December 31, 2017. Patients from the MSK cohort

estimated recurrence-free and overall

received chemoradiation, surgery, and adjuvant chemotherapy from January 1, 1998, to December

survival.

31, 2014; these patients were randomly assigned to either a model training group or an internal
validation group. Models were externally validated using data from the SCC cohort, who received
either chemoradiation, surgery, and adjuvant chemotherapy (chemoradiotherapy group) or shortcourse radiotherapy, consolidation chemotherapy, and surgery (total neoadjuvant therapy with
short-course radiotherapy group) from January 1, 2009, to December 31, 2017. Data were analyzed
from March 1, 2020, to January 10, 2021.

Meaning The results of this study
suggest that among patients with rectal
cancer who receive multimodal
treatment, these clinical calculators may
be used to inform posttreatment
surveillance strategies and aid risk
stratification in clinical trials.

EXPOSURES Chemotherapy, radiotherapy, chemoradiotherapy, and surgery.
MAIN OUTCOMES AND MEASURES Recurrence-free survival and OS were the outcome measures,
and the discriminatory performance of the clinical calculators was measured with concordance index
and calibration plots. The ability of the clinical calculators to predict RFS and OS was compared with

+ Supplemental content
Author affiliations and article information are
listed at the end of this article.

that of the AJCC staging system and the NAR score. The models for RFS and OS among patients with
incomplete pathological response included postoperative pathological tumor category, number of
positive lymph nodes, tumor distance from anal verge, and large- and small-vessel venous and
perineural invasion; age was included in the risk model for OS. The final clinical calculators provided
RFS and OS estimates derived from Kaplan-Meier curves for patients with complete pathological
response and from risk models for patients with incomplete pathological response.
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Abstract (continued)

RESULTS Among 1400 total patients with locally advanced rectal cancer, the median age was 57.8
years (range, 18.0-91.9 years), and 863 patients (61.6%) were male, with tumors at a median distance
of 6.7 cm (range, 0-15.0 cm) from the anal verge. The MSK cohort comprised 1069 patients; of those,
710 were assigned to the model training group and 359 were assigned to the internal validation
group. The SCC cohort comprised 331 patients; of those, 200 were assigned to the
chemoradiotherapy group and 131 were assigned to the total neoadjuvant therapy with short-course
radiotherapy group. The concordance indices in the MSK validation data set were 0.70 (95% CI,
0.65-0.76) for RFS and 0.73 (95% CI, 0.65-0.80) for OS. In the external SCC data set, the
concordance indices in the chemoradiotherapy group were 0.71 (95% CI, 0.62-0.81) for RFS and 0.72
(95% CI, 0.59-0.85) for OS; the concordance indices in the total neoadjuvant therapy with shortcourse radiotherapy group were 0.62 (95% CI, 0.49-0.75) for RFS and 0.67 (95% CI, 0.46-0.84) for
OS. Calibration plots confirmed good agreement between predicted and observed events. These
results compared favorably with predictions based on the AJCC staging system (concordance indices
for MSK validation: RFS = 0.69 [95% CI, 0.64-0.74]; OS = 0.67 [95% CI, 0.58-0.75]) and the NAR
score (concordance indices for MSK validation: RFS = 0.56 [95% CI, 0.50-0.63]; OS = 0.56 [95% CI,
0.46-0.66]). Furthermore, the clinical calculators provided more individualized outcome estimates
compared with the categorical schemas (eg, estimated RFS for patients with AJCC stage IIIB disease
ranged from 7% to 68%).
CONCLUSIONS AND RELEVANCE In this prognostic study, clinical calculators were developed and
validated; these calculators provided more individualized estimates of the likelihood of RFS and OS
than the AJCC staging system or the NAR score among patients with rectal cancer who received
multimodal treatment. The calculators were easy to use and applicable to both short- and longcourse radiotherapy regimens, and they may be used to inform surveillance strategies and facilitate
future clinical trials and statistical power calculations.
JAMA Network Open. 2021;4(11):e2133457. doi:10.1001/jamanetworkopen.2021.33457

Introduction
The adoption of multimodal therapy for locally advanced (tumor categories 3-4 or node categories
1-2) rectal cancer, including preoperative chemotherapy and radiotherapy, has produced
improvements in cancer outcomes.1-3 Tumor regression facilitates margin-negative resection and is
associated with lower rates of local recurrence.1 The range of tumor response to neoadjuvant therapy
varies,4 and patients with complete clinical response (ie, no radiographic or endoscopic evidence of
tumor) may be candidates for observation without surgery, often referred to as watch-and-wait or
nonoperative management.5,6 Most patients have a less-than-complete response, and the extent of
tumor downsizing and downstaging is prognostic.4
Because pretreatment and postoperative staging often differ owing to tumor downstaging,
predicting outcomes in patients with rectal cancer after the receipt of neoadjuvant therapy is
challenging. The commonly used tumor, node, and metastasis (TNM) classification system of the
American Joint Committee on Cancer (AJCC) and the Union for International Cancer Control is based
on 3 anatomic features: depth of tumor invasion into the rectal wall, locoregional lymph node
metastases, and distant metastases. Using the TNM system for disease staging among patients with
tumor regression after neoadjuvant therapy can produce ambiguities. Posttreatment tumor and
node classifications and tumor regression grades can estimate recurrence4,7 but overlook many other
prognostic features.8 In addition, grouping patients according to AJCC classification–based or tumor
regression grade–based risk categories assumes homogeneity within groups, whereas outcomes
often vary widely among patients within each group.9,10
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Clinical calculators are built on multivariable models that can incorporate a wide variety of
clinical, histological, and pathological variables.11 The models are not limited to discrete factors and
can incorporate continuous variables with nonlinear associations. Because of their superior
predictive accuracy compared with traditional staging systems,9,10 clinical calculators have recently
been endorsed by the AJCC, and the AJCC Molecular Modelers Working Group has developed
guidelines for model creation that emphasize performance measures, implementation clarity, and
clinical relevance.12
The goal of this prognostic study was to develop clinical calculators for predicting recurrencefree survival (RFS) and overall survival (OS) after the receipt of multimodal therapy among patients
with locally advanced rectal cancer. The model was validated in separate internal and external
cohorts of patients who received long-course chemoradiotherapy as well as short-course
radiotherapy followed by chemotherapy and delayed surgery, a form of total neoadjuvant therapy.

Methods
Patients and Treatments
This prognostic study was approved by the institutional review boards of the Memorial Sloan
Kettering (MSK) Cancer Center in New York, New York, and the Siteman Cancer Center (SCC) of
Washington University in St. Louis, Missouri. A waiver of informed consent was granted based on the
study’s use of deidentified data sets. This study followed the Transparent Reporting of a Multivariable
Prediction Model for Individual Prognosis or Diagnosis (TRIPOD) reporting guideline for
prognostic studies.
Prospectively maintained institutional databases were queried for patients with pretreatment
rectal adenocarcinoma within 15 cm of the anal verge that was diagnosed as AJCC stage II or III
disease via endorectal ultrasonography or magnetic resonance imaging who received treatment
between January 1, 1998, and December 31, 2017. Patients in the MSK cohort received
chemoradiotherapy followed by surgery and planned adjuvant chemotherapy between January 1,
1998, and December 31, 2014. Patients in the SCC cohort received either (1) chemoradiotherapy,
surgery, and adjuvant chemotherapy (chemoradiotherapy group) or (2) short-course radiotherapy,
chemotherapy (with either consolidation leucovorin, fluorouracil, and oxaliplatin [FOLFOX] or
consolidation capecitabine and oxaliplatin [CAPOX]), and surgery (total neoadjuvant therapy with
short-course radiotherapy group) between January 1, 2009, and December 31, 2017. The surgical
procedure for all patients was total mesorectal excision. Patients with metastatic disease and those
with cancer that was being managed by a watch-and-wait strategy (which was rare during the study
period) were excluded. The regimens for chemoradiotherapy with adjuvant chemotherapy and
short-course radiotherapy with consolidation chemotherapy (ie, total neoadjuvant therapy) are
available in the eMethods in Supplement 1.13,14

Characteristics and Outcomes
Demographic, clinical, and pathological characteristics as well as follow-up data of 1400 patients
were retrieved from institutional databases and manually reviewed via the electronic medical record.
Pretreatment characteristics included patient age (patient race and ethnicity were not examined
because these characteristics were not reliably reported in the data sets), tumor distance from the
anal verge, AJCC clinical tumor (cT) classification, and AJCC clinical node (cN) classification. Time
from the end of radiotherapy to surgery was also retrieved, as were the following postresection
tumor characteristics: AJCC postoperative pathological tumor (ypT) classification, AJCC
postoperative pathological node (ypN) classification, presence of lymphovascular large and small
venous invasion (venous invasion), presence of perineural invasion (PNI), number of resected lymph
nodes, and number of lymph nodes with metastasis (positive lymph nodes). Downstaging was
determined using the 5th edition of the AJCC Cancer Staging Manual (AJCC-5)15 rather than the 8th
edition (AJCC-8) because accurate pretreatment discrimination of N1 vs N2 disease is limited by
JAMA Network Open. 2021;4(11):e2133457. doi:10.1001/jamanetworkopen.2021.33457 (Reprinted)
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current staging modalities. Downstaging was calculated by comparing pretreatment cT category, cN
category, and AJCC-5 disease stage with ypT category, ypN category, and AJCC-5 disease stage.
Postoperative surveillance was performed in accordance with guidelines from the National
Comprehensive Cancer Network.16 Recurrence was identified based on radiographic evidence (with
or without biopsy), colonoscopy results, and serum carcinoembryonic antigen levels.
The outcome measures were RFS and OS. Recurrence-free survival was defined as the period
from the date of surgery to the date of recurrence or death, and patients alive without recurrence
were censored at the last follow-up. Overall survival was defined as the period from the date of
surgery to the date of death associated with any cause, and patients alive were censored at the last
follow-up.

Development of Clinical Calculators
The MSK cohort was randomly split into a model training group (two-thirds of patients) and an
internal validation group (one-third of patients), which were stratified by year of surgery to ensure
appropriate temporal representation during the study period. Models were developed using the MSK
training data set and validated using the MSK validation data set and the 2 SCC data sets from the
chemoradiotherapy group and the total neoadjuvant therapy with short-course radiotherapy group.
Because patients with complete pathological response (ypT0N0) after the receipt of
neoadjuvant therapy had a substantially lower likelihood of recurrence and a higher rate of survival
compared with other patients,4 an a priori decision was made to obtain RFS and OS estimates from
Kaplan-Meier curves using data from patients with complete pathological response and to create risk
models for predicting RFS and OS using data from patients with incomplete pathological response.
For patients with incomplete pathological response, a univariate proportional hazards
regression model was used to evaluate the association of baseline characteristics with RFS and OS.
We selected clinically relevant, universally measured variables regardless of whether they were
significantly associated with outcomes, and we avoided collinearity. An algorithm was then applied
to identify the best-fitting model, defined as the model with the highest χ2 value.17 To permit
nonlinear associations, restricted cubic splines were used for continuous variables in the risk model.18
For RFS and OS, the final Cox proportional hazards model included ypT category, number of positive
lymph nodes, tumor location (distance from the anal verge of <5 cm vs ⱖ5 cm), presence of venous
invasion, and presence of PNI. The OS model also included patient age. Interaction terms between
these covariates were not considered in the final models. The proportional hazards assumption was
confirmed using the Schoenfeld test, and the graphical diagnostic results were based on scaled
Schoenfeld residuals.19 The final clinical calculators predicted RFS and OS using Kaplan-Meier curves
for patients with complete pathological response (ypT0N0) and risk models for patients with
incomplete pathological response, which were graphically shown as nomograms.

Statistical Analysis
The discriminatory performance of each clinical calculator for RFS and OS was measured with the
concordance index using the MSK validation data set and the 2 SCC data sets. The concordance index
was calculated using inverse probability weights for up to 80 months for RFS and up to 60 months
for OS.20 The concordance index represented the probability that, given 2 randomly selected
patients, the patient who had a recurrence first had a higher predicted probability of recurrence.
Values were interpreted similarly to the area under the receiver operating characteristic curve, with
0.5 corresponding to random chance and 1.0 corresponding to correct predictions for all patients.21 A
concordance index was estimated for the entire population (patients with complete and incomplete
pathological response) for the 2 outcomes, and bootstrap 95% CIs were calculated.20
The clinical calculators were also evaluated using calibration curves, which were created by
plotting the predicted RFS and OS at 5 years against the observed outcomes for the MSK validation
group and the 2 SCC groups. If the points were on or near the 45-degree line, the model was
considered to have good calibration, with a predicted outcome that matched the observed outcome.
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If the points were higher than the 45-degree line, the model was considered to underestimate
outcome probabilities. If the points were lower than the 45-degree line, the model was considered to
overestimate outcome probabilities.
Using the concordance index, the predictive accuracies of the clinical calculators were
compared with the predictive accuracies of the AJCC-8 staging system22 and the neoadjuvant rectal
(NAR) score.23,24 Although the NAR score was developed as a surrogate end point for clinical trials of
total neoadjuvant therapy, the score has been more recently used as a single prognostic factor.23 The
NAR score was calculated using the AJCC cT classification, the AJCC ypT classification, and the AJCC
ypN classification according to the following steps: (1) the ypT category was subtracted from the cT
category and then multiplied by 3; (2) the resulting value was subtracted from the product of 5
multiplied by the ypN category; (3) the resulting value was added to 12 and then squared; and (4) the
resulting value was divided by 9.61. With 4 possible values for cT (cT1-cT4), 5 possible values for ypT
(ypT0-ypT4), and 3 possible values for ypN (ypN0-ypN2), the NAR score could have 24 discrete
values between 0 and 100. Because the NAR score was intended to be used as a surrogate end point
for clinical trials of rectal cancer, most studies have categorized risk based on 3 NAR score categories
(<8 points, 8-16 points, and >16 points) for estimation of outcomes.24-26
All statistical analyses were performed using SAS software, version 9.4 (SAS Institute Inc), or R
software, version 3.6.0 (R Foundation for Statistical Computing). All P values were 2-sided, and P < .05
was considered statistically significant. Data were analyzed from March 1, 2020, to January 10, 2021.

Results
Cohorts
Of 1400 total patients with locally advanced rectal cancer included in the study, 1069 patients
received treatment at MSK, and 331 patients received treatment at SCC. Among those in the MSK
cohort, 710 patients were assigned to the model training group, and 359 were assigned to the
internal validation group. In the SCC cohort, 200 patients were assigned to the chemoradiotherapy
group, which received treatment similar to that received by the MSK cohort (chemoradiotherapy,
surgery, and adjuvant chemotherapy), and 131 patients were assigned to the total neoadjuvant
therapy with short-course radiotherapy group, which received short-course radiotherapy;
consolidation leucovorin, fluorouracil, and oxaliplatin (FOLFOX) chemotherapy or consolidation
capecitabine and oxaliplatin (CAPOX) chemotherapy; and surgery.
Among all patients, the median age was 57.8 years (range, 18.0-91.9 years); 863 patients (61.6%)
were male, and 537 patients (38.4%) were female, with tumors at a median distance of 6.7 cm (range,
0-15.0 cm) from the anal verge (Table). Preoperative clinical stages (AJCC cT and cN categories) did not
differ significantly between the MSK and SCC cohorts, with cT3N1/2 disease being the most common
(eg, cT3: 865 patients [80.9%] in the MSK cohort vs 261 patients [78.9%] in the SCC cohort; cN1/2: 724
patients [67.7%] in the MSK cohort vs 236 patients [71.3%] in the SCC cohort). The median time from
the end of radiotherapy to surgery was 7.1 weeks (range, 2.0-9.7 weeks) in the MSK training group, 7.1
weeks (range, 4.0-19.9 weeks) in the MSK validation group, 9.0 weeks (range, 2.9-19.9 weeks) in the
SCC chemoradiotherapy group, and 18.7 weeks (range, 12.4-32.0 weeks) in the SCC total neoadjuvant
therapy with short-course radiotherapy group. Patients were also classified based on complete pathological response (212 patients [19.8%] in the MSK cohort vs 65 patients [19.6%] in the SCC cohort with
complete pathological response), AJCC ypT category (eg, 308 patients [28.8%] in the MSK cohort vs
92 patients [27.8%] in the SCC cohort with ypT2 disease), AJCC ypN category (eg, 805 patients [75.3%]
in the MSK cohort vs 235 patients [71.0%] in the SCC cohort with ypN0 disease), AJCC-8 pathological
stage (eg, 303 patients [28.3%] in the MSK cohort vs 90 patients [27.2%] in the SCC cohort with stage I
disease), number of lymph nodes evaluated (median, 13 nodes [range, 0-47 nodes] in the MSK training
set, 14 nodes [range, 1-107 nodes] in the MSK validation set, 14 nodes [range, 0-42 nodes] in the SCC
chemoradiotherapy group, and 15 nodes [range, 0-41 nodes] in the SCC short-course radiotherapy with
consolidation chemotherapy group), number of positive lymph nodes (median, 2 nodes [range, 1-18
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Table. Patient and Disease Characteristics
Patients, No. (%)
MSK cohort

SCC cohort
Short-course
radiotherapy
validation group

Model training
group

Validation
group

Chemoradiotherapy
validation group

Total patients, No.

710

359

200

131

Age, median (range), y

58.0 (18.0-89.0)

58.0 (24.0-87.0)

57.3 (31.3-91.9)

57.3 (33.2-85.0)

Female

276 (38.9)

148 (41.2)

70 (35.0)

43 (32.8)

Male

434 (61.1)

211 (58.8)

130 (65.0)

88 (67.2)

DTAV, median (range), cm

7 (0-15)

6 (1-15)

6 (0-14)

8 (0-14)

Time from radiotherapy to
surgery, median (range), wk

7.1 (2.0-9.7)

7.1 (4.0-19.9)

9.0 (2.9-19.9)

18.7 (12.4-32.0)

1

5 (0.7)

1 (0.3)

1 (0.5)

1 (0.8)

2

39 (5.5)

23 (6.4)

16 (8.0)

10 (7.6)

3

580 (81.7)

285 (79.4)

156 (78.0)

105 (80.2)

4

19 (2.7)

16 (4.5)

24 (12.0)

14 (10.7)

Unknown

67 (9.4)

34 (9.5)

3 (1.5)

1 (0.8)

0

148 (20.8)

82 (22.8)

63 (31.5)

31 (23.7)

1/2

485 (68.3)

239 (66.6)

136 (68.0)

100 (76.3)

Unknown

77 (10.8)

38 (10.6)

1 (0.5)

0

II

148 (20.8)

82 (22.8)

61 (30.5)

30 (22.9)

III

485 (68.3)

239 (66.6)

136 (68.0)

100 (76.3)

Unknown

77 (10.8)

38 (10.6)

3 (1.5)

1 (0.8)

Complete

141 (19.9)

71 (19.8)

34 (17.0)

31 (23.7)

Incomplete

567 (79.9)

288 (80.2)

166 (83.0)

100 (76.3)

Unknown

2 (0.3)

0

0

0

0

146 (20.6)

72 (20.1)

37 (18.5)

34 (26.0)

1

46 (6.5)

28 (7.8)

12 (6.0)

12 (9.2)

2

207 (29.2)

101 (28.1)

48 (24.0)

44 (33.6)

3

294 (41.4)

145 (40.4)

93 (46.5)

38 (29.0)

4

16 (2.3)

13 (3.6)

10 (5.0)

3 (2.3)

Unknown

1 (0.1)

0

0

0

0

534 (75.2)

271 (75.5)

139 (69.5)

96 (73.3)

1

133 (18.7)

64 (17.8)

43 (21.5)

30 (22.9)

2

41 (5.8)

24 (6.7)

18 (9.0)

5 (3.8)

Unknown

2 (0.3)

0

0

0

0

141 (19.9)

71 (19.8)

34 (17.0)

31 (23.7)

I

196 (27.6)

107 (29.8)

49 (24.5)

41 (31.3)

IIA

186 (26.2)

85 (23.7)

52 (26.0)

22 (16.8)

IIB

11 (1.5)

8 (2.2)

4 (2.0)

2 (1.5)

IIIA

54 (7.6)

18 (5.0)

11 (5.5)

16 (12.2)

IIIB

111 (15.6)

64 (17.8)

42 (21.0)

18 (13.7)

IIIC

9 (1.3)

6 (1.7)

8 (4.0)

1 (0.8)

Unknown

2 (0.3)

0

0

0

Characteristic

Sex

cT category

cN category

Pretreatment AJCC-5
clinical stage

Pathological tumor
response

ypT category

ypN category

Pathological AJCC-8 stage

(continued)
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Table. Patient and Disease Characteristics (continued)
Patients, No. (%)
MSK cohort
Model training
group

Characteristic

SCC cohort
Validation
group

Chemoradiotherapy
validation group

Short-course
radiotherapy
validation group

Lymph nodes,
median (range), No.
Evaluated

13 (0-47)

14 (1-107)

14 (0-42)

15 (0-41)

Positivea

2 (1-18)

2 (1-22)

2 (1-9)

2 (1-8)

Absent

612 (86.2)

306 (85.2)

163 (81.5)

113 (86.3)

Present

88 (12.4)

51 (14.2)

27 (13.5)

15 (11.5)

Unknown

10 (1.4)

2 (0.6)

10 (5.0)

3 (2.3)

592 (83.4)

293 (81.6)

152 (76.0)

112 (85.5)

Venous invasionb

PNI
Absent
Present

104 (14.6)

59 (16.4)

29 (14.5)

13 (9.9)

Unknown

14 (2.0)

7 (1.9)

19 (9.5)

6 (4.6)

Downstaged

358 (50.4)

178 (49.6)

96 (48.0)

90 (68.7)

No change

272 (38.3)

141 (39.3)

96 (48.0)

36 (27.5)

Upstaged

13 (1.8)

6 (1.7)

5 (2.5)

4 (3.1)

Missing data

67 (9.4)

34 (9.5)

3 (1.5)

1 (0.8)

Change in tumor categoryc

Change in node category

c

Downstaged

361 (50.8)

185 (51.5)

95 (47.5)

No change

219 (30.8)

103 (28.7)

84 (42.0)

40 (30.5)

Upstaged

52 (7.3)

33 (9.2)

20 (10.0)

8 (6.1)

Missing data

78 (11.0)

38 (10.6)

1 (0.5)

0

Downstaged

435 (61.3)

220 (61.3)

122 (61.0)

88 (67.2)

No change

177 (24.9)

84 (23.4)

63 (31.5)

37 (28.2)

Upstaged

30 (4.2)

21 (5.8)

15 (7.5)

6 (4.6)

Missing data

68 (1.0)

34 (9.5)

0

0

Abbreviations: AJCC-5, AJCC Cancer Staging Manual,
5th edition15; AJCC-8, AJCC Cancer Staging Manual,
8th edition22; cN, clinical node; cT, clinical tumor;
DTAV, distance from anal verge; MSK, Memorial Sloan
Kettering Cancer Center; PNI, perineural invasion; SCC,
Siteman Cancer Center; ypN, postoperative
pathological nodal category; ypT, postoperative
pathological tumor category.
a

Among patients with positive lymph nodes.

b

Venous invasion represents small lymphatic and
venous invasion, large intramural venous invasion,
and large extramural venous invasion.

c

Change after neoadjuvant therapy. Upstaging
indicates that postoperative pathological category or
stage was higher than pretreatment clinical category
or stage; downstaging indicates that postoperative
pathological category or stage was lower than
pretreatment clinical category or stage.

d

Complete pathological response was considered
downstaging when the initial cancer stage
was missing.

83 (63.4)

Change in AJCC-5 stagec,d

nodes] in the MSK training set, 2 nodes [range, 1-22 nodes] in the MSK validation set, 2 nodes [range,
1-9 nodes] in the SCC chemoradiotherapy group, and 2 nodes [range, 1-8 nodes] in the SCC short-course
radiotherapy with consolidation chemotherapy group), presence of venous invasion (139 patients
[13.0%] in the MSK cohort vs 42 patients [12.7%] in the SCC cohort with venous invasion), presence of
PNI (163 patients [15.2%] in the MSK cohort vs 42 patients [12.7%] in the SCC cohort with PNI), and
downstaging (eg, 655 patients [61.3%] in the MSK cohort vs 210 patients [63.4%] in the SCC cohort
with AJCC-5 downstaging).

Outcomes and Clinical Calculator Variables
Of 141 patients in the MSK training group with complete pathological response (ie, ypT0N0), 17
patients (12.1%) had a recurrence, and 15 patients (10.6%) died. Based on Kaplan-Meier estimates,
the 5-year RFS and OS among 833 patients with complete pathological response were 92.0% and
93.0%, respectively (Figure 1 and Figure 2). Of the remaining 567 patients with incomplete
pathological response, 198 patients (34.9%) had a recurrence, and 148 patients (26.1%) died,
corresponding to a 5-year RFS and OS of 70.0% and 82.0%, respectively.
Independent factors associated with RFS that were included in the risk models for patients with
incomplete pathological response were ypT classification, number of positive lymph nodes, distance
from the anal verge, presence vs absence of venous invasion, and presence vs absence of PNI (eTable
in Supplement 1). The ypT1 category was grouped with the ypT0 category to create a more
parsimonious RFS model (Figure 2A).
JAMA Network Open. 2021;4(11):e2133457. doi:10.1001/jamanetworkopen.2021.33457 (Reprinted)
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Independent factors associated with OS that were included in the risk models for patients with
incomplete pathological response were age, ypT classification, number of positive lymph nodes,
distance from the anal verge, presence vs absence of venous invasion, and presence vs absence of

Figure 1. Kaplan-Meier 5-Year Recurrence-Free Survival Among Patients With Complete vs Incomplete
Pathological Response to Adjuvant Chemoradiotherapy
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Figure 2. Nomogram of Risk Model for Predicting Recurrence-Free Survival and Overall Survival
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PNI (eTable in Supplement 1). The ypT0, ypT1, and ypT2 categories were grouped together to create
a more parsimonious OS model (Figure 2B). Equations used to predict RFS and OS among those with
incomplete pathological response are provided in the eFigure in Supplement 1.

Validation
The RFS and OS clinical calculators for patients with complete vs incomplete pathological response
were validated using data from the MSK validation group and the 2 SCC validation groups (ie, the
chemoradiotherapy group and the total neoadjuvant therapy with short-course radiotherapy group).
The discriminatory performance of the clinical calculators, the AJCC-8 staging system, and the NAR
score were measured with the concordance index.
For predicting RFS in the MSK validation group, the concordance indices were 0.70 (95% CI,
0.65-0.76) for the clinical calculator, 0.69 (95% CI, 0.64-0.74) for the AJCC-8 staging system, and
0.56 (95% CI, 0.50-0.63) for the NAR score. For predicting RFS in the SCC chemoradiotherapy
group, the concordance index was 0.71 (95% CI, 0.62-0.81) for the clinical calculator, 0.68 (95% CI,
0.60-0.75) for the AJCC-8 staging system, and 0.67 (95% CI, 0.59-0.76) for the NAR score. For
predicting RFS in the SCC total neoadjuvant therapy with short-course radiotherapy group, the
concordance indices were 0.62 (95% CI, 0.49-0.75) for the clinical calculator, 0.63 (95% CI,
0.52-0.73) for the AJCC-8 staging system, and 0.60 (95% CI, 0.49-0.73) for the NAR score.
For predicting OS in the MSK validation group, the concordance indices were 0.73 (95% CI,
0.65-0.80) for the clinical calculator, 0.67 (95% CI, 0.58-0.75) for the AJCC-8 staging system, and
0.56 (95% CI, 0.46-0.66) for the NAR score. For predicting OS in the SCC chemoradiotherapy group,
the concordance indices were 0.72 (95% CI, 0.59-0.85) for the clinical calculator, 0.64 (95% CI,
0.53-0.74) for the AJCC-8 staging system, and 0.69 (95% CI, 0.57-0.81) for the NAR score. For
predicting OS in the SCC total neoadjuvant therapy with short-course radiotherapy group, the
concordance indices were 0.67 (95% CI, 0.46-0.84) for the clinical calculator, 0.60 (95% CI, 0.450.77) for the AJCC-8 staging system, and 0.60 (95% CI, 0.47-0.79) for the NAR score.
The calibration plots for predicting 5-year RFS and OS using the clinical calculators in the validation
data sets are shown in Figure 3. The plot of predicted outcome (RFS or OS) vs observed outcome (RFS
or OS) approximated a 45-degree diagonal for all 3 validation data sets. The range of 5-year RFS estimates within each AJCC-8 disease substage for the 1069 patients in the MSK cohort is shown in
Figure 4. For example, the RFS for patients with AJCC stage IIIB cancer ranged from 7% to 68%.

Discussion
In this prognostic study, the MSK clinical calculators, which incorporated clinical, histological, and
AJCC pathological variables, outperformed the AJCC-8 staging system and the NAR score for
predicting RFS and OS among patients with locally advanced rectal cancer who received multimodal
treatment. The concordance indices of the clinical calculators were modestly higher than those of
the AJCC-8 staging system; however, the AJCC-8 categorical system assumes homogeneity and
cannot discriminate between outcomes within disease substages. In contrast, the MSK clinical
calculators could discriminate errant outcomes within each substage by providing continuous
estimates of risk. For example, among patients in the MSK cohort who had AJCC stage IIIB disease
(67% of patients with stage III disease), the 5-year RFS was 48%, but the clinical calculator–predicted
RFS for patients with stage IIIB disease ranged from 7% to 68% (Figure 4). Thus, the MSK clinical
calculators provided more individualized data via judicious use of all available relevant information.
The outperformance of the NAR score by our clinical calculators was consistent with the
findings of a recent study outlining the limitations of the NAR score.25 In addition to the restrictions
imposed by a categorical system, the inadequate performance of the clinical calculators may be
associated with inaccurate pretreatment clinical staging.1 Response to neoadjuvant therapy is a
measure of tumor biology that is not fully captured by baseline characteristics and is more prognostic
than pretreatment clinical staging.4
JAMA Network Open. 2021;4(11):e2133457. doi:10.1001/jamanetworkopen.2021.33457 (Reprinted)
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Radiotherapy has been used for the treatment of rectal cancer for the past 4 decades with the aim
of reducing high rates of local recurrence after rectal resection. Prospective randomized clinical trials
have demonstrated that postoperative chemoradiotherapy (45-54 Gy delivered in 25-28 fractions with
radiosensitizing fluorouracil) can significantly reduce the likelihood of local recurrence after rectal cancer resection.2 Preoperative chemoradiotherapy was subsequently reported to further reduce the likelihood of local recurrence and lessen toxic effects.1 In those studies,1,2 surgery was routinely performed
6 weeks after the receipt of neoadjuvant therapy, and rectal cancer response was evident in tumor
downsizing, tumor downstaging, and tumor regression.7

Figure 3. Calibration Curves for 5-Year Recurrence-Free Survival (RFS) and Overall Survival (OS)
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In short-course radiotherapy, a total dose of 25 Gy is administered in 5 fractions, which is
biologically equivalent to long-course radiotherapy. Early studies found that performing surgery
immediately after receipt of short-course radiotherapy did not allow sufficient time for tumor

Figure 4. Heterogeneity of Clinical Calculator–Predicted Probabilities of 5-Year Recurrence-Free Survival (RFS)
in the Memorial Sloan Kettering Cancer Center Cohort
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downsizing or downstaging but reduced the likelihood of local recurrence.3,27 A later study reported
that delaying surgery after short-course radiotherapy allowed the tumor to respond,28 and the
addition of consolidation chemotherapy, which was implemented in the total neoadjuvant therapy
arm of the RAPIDO (Rectal Cancer and Preoperative Induction Therapy Followed by Dedicated
Operation) clinical trial, further enhanced the response.29
Although our clinical calculators were developed using data from patients who received
neoadjuvant chemoradiotherapy, the calculators are likely broadly applicable because they were
validated using data from patients who received short-course radiotherapy with consolidation
chemotherapy, a form of total neoadjuvant therapy.29 Only a few previous clinical calculators
developed to predict rectal cancer recurrence and patient survival have undergone appropriate
external validation. One such calculator, developed by Valentini et al30 for predicting rectal cancer
recurrence, metastasis, and patient survival after radiotherapy or chemoradiotherapy (based on data
from European phase III clinical trials conducted between 1992 and 2003), includes dose of
radiotherapy, concomitant use of chemotherapy and radiotherapy, adjuvant chemotherapy, clinical
and pathological AJCC tumor and node categories, and procedure performed (rather than specific
location of the tumor). The concordance index for that clinical calculator was similar to the indices of
our clinical calculators, suggesting comparable discrimination; however, the Valentini et al30 study
had statistical limitations because it performed imputation without penalty and did not address the
competing risk of local and distant recurrence. Furthermore, the model in that study was less
applicable to patients receiving contemporary standard radiotherapy and chemotherapy regimens as
well as newer multimodal treatments, such as total neoadjuvant therapy.
The lower predictive accuracy (as measured by the concordance index) of the clinical calculators
compared with those of colon cancer models31,32 may be associated with tumor response to
multimodality therapy and represents an opportunity for improvement, possibly with the future
addition of molecular and/or radiographic variables to the model, which capture the dynamics of
tumor regression. The present study designed a web interface33 incorporating estimates from
Kaplan-Meier curves for patients with complete response and risk models (depicted using
nomograms) for patients with incomplete response to provide an easy-to-use method for patients
and physicians to calculate the likelihood of 5-year RFS and OS.

Limitations
This study has limitations. It is subject to the selection bias inherent in any retrospective study, which
we minimized by closely following the methodological criteria established by the AJCC Precision
Medicine Core.12 This adherence to standards is especially important given that most prognostic
tools for colorectal cancer have methodological deficiencies.34 Other strengths include the relatively
large cohort of patients who underwent standardized resection procedures, comprehensive
histological assessment by specialized pathologists, and the availability of granular clinical and
demographic information. Another advantage of the study is the rigorous validation performed using
both internal (MSK) and external (SCC) independent data sets, which addresses the common
concern about the applicability of risk models developed from single-institution data. The validation
results suggest that our predictions may be relevant to the general population.

Conclusions
In this prognostic study, the clinical calculators provided more individualized estimates of the
likelihood of rectal cancer recurrence and patient survival than the AJCC staging system or the NAR
score. These estimates can be used to inform surveillance routines and aid risk stratification in
clinical trials.
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